Author:
Rose C.,Vtoraya O.,Pluzanska A.,Davidson N.,Gershanovich M.,Thomas R.,Johnson S.,Caicedo J.J.,Gervasio H.,Manikhas G.,Ben Ayed F.,Burdette-Radoux S.,Chaudri-Ross H.A.,Lang R.
Reference27 articles.
1. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer;Dowsett;Endocr.-Relat. Cancer,2001
2. Aromatase inhibitors in the treatment and prevention of breast cancer;Goss;J. Clin. Oncol.,2001
3. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer;Buzdar;J Clin Oncol.,1996
4. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate;Buzdar;J. Clin. Oncol.,2001
5. Letrozole, a new oral aromatase inhibitor for advanced breast cancer;Dombernowsky;J. Clin. Oncol.,1998